Meta-analysis of the prognostic value of long non-coding RNA PVT1 for cancer patients

Chao Ma, MD\textsuperscript{a}, Xing-Guo Nie, MD\textsuperscript{a}, Yan-Li Wang, MD\textsuperscript{b}, Da-Peng Wu, MD\textsuperscript{a},* Qiu-dong Liang, MD\textsuperscript{a,*} 

Abstract

Background: Plasmacytoma variant translocation 1 (PVT1) is reported to be deregulated in various cancers. Therefore, this meta-analysis was performed to clarify its utility as a prognosis marker in malignant tumors.

Methods: Electronic databases, including PubMed, OVID, Cochrane Library, and Web of Science databases, were retrieved from inception to December 16, 2017. Typically, hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were calculated, so as to explore the relationship between PVT1 expression and patient survival. In addition, odds ratios (OR) were calculated to assess the association of PVT1 expression with pathological parameters.

Results: A total of 23 studies involving 2350 patients were included in this meta-analysis. The pooled HR suggested that high PVT1 expression levels were correlated with poor overall survival (OS, HR\textsuperscript{adj} = 1.79, 95% CI: 1.39–2.30), disease-free survival (DFS, HR\textsuperscript{adj} = 1.76, 95% CI: 1.45–2.14), and recurrence-free survival (RFS, HR\textsuperscript{adj} = 1.74, 95% CI: 1.26–2.39) in cancer patients without obvious heterogeneity. Moreover, high PVT1 expression levels were also correlated with larger tumor size (HR\textsuperscript{adj} = 1.47, 95% CI: 1.02–2.11), poor differentiation grade (OR\textsuperscript{adj} = 1.79, 95% CI: 1.39–2.30), advanced tumor stage (pooled OR\textsuperscript{adj} = 3.28, 95% CI: 2.46–4.38), lymph node metastasis (OR\textsuperscript{adj} = 2.67, 95% CI: 1.66–4.29) and distant metastasis (OR\textsuperscript{adj} = 4.00, 95% CI: 1.39–11.50) in cancer patients.

Conclusions: Findings of this meta-analysis suggest that a high PVT1 expression level may serve as a novel biomarker of poor prognosis in cancers.

Abbreviations: ANT = adjacent noncancerous tissue, BC = bladder cancer, CI = confidence interval, CRC = colorectal cancer, CVC = cervical cancer, DFS = disease-free survival, DM = distant metastasis, ESCC = esophageal squamous cell carcinoma, GC = gastric cancer, HCC = hepatocellular carcinoma, HR = hazard ratio, LNM = lymph node metastasis, NSCLC = non-small cell lung cancer, OR = odds ratio, OS = overall survival, OSC = osteosarcoma, PC = pancreatic cancer, PHG = poor histological grade, PVT1 = Plasmacytoma variant translocation 1, RFS = recurrence-free survival, SCLC = small cell lung cancer, TS = high tumor stage.

Keywords: meta-analysis, metastasis, neoplasms, prognosis, PVT1

1. Introduction

According to statistics, the U.S. has witnessed approximately 1.7 million new cancer cases and 600,000 cancer-related deaths in 2017.\textsuperscript{[11]} Unfortunately, the 5-year survival rates for most cancers remain dismal, and many scientists are looking for new biomarkers to improve the diagnosis and prognosis in cancers. Therefore, great efforts have been made to develop new prognostic markers to facilitate their clinical application in cancers.

2. Materials and methods

2.1. Literature collection

According to the standard guidelines of meta-analysis,\textsuperscript{[15,16]} the following electronic databases, including PubMed, OVID,
and Web of Science for relevant articles, were systemically retrieved by 2 authors independently, to collect studies regarding PVT1 as a prognostic marker for survival of cancer patients. The latest retrieval was updated on December 16, 2017. Specifically, literature retrieval was performed by means of both text word and MeSH strategy using the terms “PVT1”, “PVT1”, “lncRNA” or “noncoding RNA” or “long intergenic noncoding RNA”, “carcinoma” or “neoplasm” or “tumor” or “cancer”, “prognostic” or “prognosis”, “outcome” or “survival” or “recurrence”. Notably, the strategy was correspondingly adjusted in different databases. In the retrieval process, a manual retrieval was also carried out using the reference lists from relevant articles to recruit eligible studies. All analyses were performed based on previously published studies. Thus, no ethic approval and informed consent were required in this study.

2.2. Study selection

All the included studies were evaluated and data were extracted by two researchers independently. The study inclusion criteria were as follows:
1. studies in which the role of PVT1 in the development of human cancer was investigated;
2. studies that described the related clinicopathological parameters;
3. studies that measured the PVT1 expression levels in human tumor tissues; and
4. studies in which patients were grouped according to the PVT1 expression levels.

The study exclusion criteria were as follows:
1. reviews, letters, editorials, case reports, and expert opinions;
2. non-English language and non-human studies;

Figure 1. Flowchart showing the steps of study selection in this meta-analysis.
## Table 1
The basic information and data of all included studies in the meta-analysis.

| Study     | Year | Region | Tumor type | Sample size | Total PHG | HTS | Total PHG | HTS | Cut-off value | HR (95% CI) | Reference gene | Method |
|-----------|------|--------|------------|-------------|-----------|-----|-----------|-----|---------------|-------------|----------------|--------|
| Chen[19]  | 2017 | China  | GC         | 187         | 112       | 28  | 91        | 19  | 59           | 1.455 (1.005–2.105) | YD         | PCR             |
| Cui[20]   | 2016 | China  | NSCLC      | 108         | 53        | 16  | 28        | 55  | 16           | 1.72 (1.14–2.52)   | GAPDH      | PCR             |
| Cui[21]   | 2017 | China  | BC         | 146         | 73        | 54  | 46        | 73  | 40           | 2.00 (1.08–3.79)   | GAPDH      | PCR             |
| Ding[22]  | 2014 | China  | GC         | 31          | 19        | 14  | 12        | 12  | 4            | –            | –               | B-actin |
| Ding[23]  | 2015 | China  | HCC        | 214         | 85        | 67  | 24        | 18  | 16           | –            | 3.013 (1.574–6.673) | GAPDH   | PCR             |
| Huang[24] | 2015 | China  | PC         | 85          | 67        | 62  | 46        | 18  | 16           | –            | GAPDH          | PCR     |
| Huang[25] | 2016 | China  | SCLC       | 146         | 73        | 54  | 46        | 73  | 40           | 1.782 (1.078–2.945) | GAPDH      | PCR             |
| Ding[26]  | 2017 | China  | GC         | 31          | 19        | 14  | 12        | 12  | 4            | –            | –               | B-actin |
| Kong[27]  | 2015 | China  | GC         | 80          | 40        | 28  | 26        | 40  | 20           | 2.092 (1.068–4.096) | GAPDH      | PCR             |
| Lan[28]   | 2016 | China  | HCC        | 48          | 24        | 5   | 19        | 24  | 4            | 1.76 (1.041–2.977)  | GAPDH      | PCR             |
| Li[29]    | 2016 | China  | CRC        | 30          | 15        | 5   | 15        | 15  | 6            | –            | –               | GAPDH   |
| Li[30]    | 2015 | China  | ESCC       | 104         | 52        | 19  | 31        | 52  | 8            | 2.75 (1.35–5.90)   | GAPDH      | PCR             |
| Song[31]  | 2017 | China  | OSC        | 46          | 24        | 16  | 22        | 22  | 3            | 2.37 (1.219–4.609)  | GAPDH      | PCR             |
| Takahashi[11] | 2014 | Japan  | CRC        | 164         | 131       | 10  | 74        | 33  | 2            | 2.532 (1.152–10.747) | GAPDH      | PCR             |
| Wang[23]  | 2016 | China  | NSCLC      | 105         | 56        | 29  | 49        | 11  | 11           | 2.464 (1.214–4.999) | GAPDH      | PCR             |
| Xu[42]    | 2014 | China  | HCC        | 89          | 45        | 14  | 44        | 9   | –            | 1.98 (1.15–4.17)   | B-actin    | PCR             |
| Yang[43]  | 2014 | China  | HCC        | 190         | 98        | –   | 94        | –   | –            | 1.64 (1.15–2.30)   | B-actin    | PCR             |
| Yuan[44]  | 2016 | China  | GC         | 85          | 44        | 31  | 43        | 43  | 21           | 2.27 (1.24–4.15)   | GAPDH      | PCR             |
| Zhang[45] | 2017 | China  | GC         | 87          | 44        | –   | 31        | 43  | 21           | 2.27 (1.24–4.15)   | GAPDH      | PCR             |
| Zhao[46]  | 2017 | China  | PC         | 34          | 18        | 16  | 16        | 16  | 5            | –            | –               | B-actin |
| Zheng[47] | 2016 | China  | ESCC       | 77          | 39        | 27  | 38        | 38  | 15           | –            | –               | GAPDH   |
| Zhuang[48] | 2015 | China  | BC         | 32          | 20        | 12  | 19        | 12  | 2            | –            | –               | GAPDH   |

Note: The dashes represent no data.

ANT = adjacent noncancerous tissue, BC = bladder cancer, CRC = colorectal cancer, CVC = cervical cancer, ESCC = esophageal squamous cell carcinoma, GC = gastric cancer, HCC = hepatocellular carcinoma, HR = hazard ratio, NSCLC = non-small cell lung cancer, OS = overall survival, OSC = osteosarcoma, PC = pancreatic cancer, PHG = poor histological grade, SCLC = small cell lung cancer, TS = high tumor stage, YD = Youden’s index.
3. studies without available data; and
4. laboratory studies mentioning the molecular structure and functions of PVT1 alone.

2.3. Data extraction

Data from the original articles were extracted and examined by 2 reviewers independently. Any disagreements in the literature assessment were resolved through consensus with a third reviewer. The following data were extracted: surname of the first author, publication year, country, tumor type, sample size, the cut-off value of PVT1 expression, the number of patients with poor histological grade and high tumor stage, adjusted HR and 95% CI of elevated PVT1 for OS, the reference gene of PVT1, and detection method of PVT1.

2.4. Statistical methods

The statistical analyses were performed using the Stata version 12.0 software. The heterogeneities among different studies were measured by Q and I² tests, respectively. Typically, a probability value of $I^2 \geq 50\%$ and $P < .1$ indicated the presence of significant heterogeneity. Moreover, a random effects model or fixed effects model was employed depending on the results of the heterogeneity analysis. To be specific, the random-effects model was adopted in the presence of significant heterogeneity among studies. In addition, the potential publication bias was assessed by Begg’s funnel plot. The pooled hazard ratios (HRs) and odds ratios (ORs) were extracted from the published data. For HRs that could be obtained directly from the publications, the crude ones were adopted; while for HR and 95% that were not directly reported in the studies, the survival data were extracted from Kaplan–Meier curve to estimate HR. Moreover, the log HR and standard error (SE) were used to summarize the OS outcome. Importantly, the ORs and their 95% CIs were combined to assess the association of PVT1 expression with clinicopathological parameters, including tumor size, differentiation grade, tumor stage, LNM, and DM.

3. Results

3.1. Study characteristics

The detailed screening process is shown in Figure 1. According to the study inclusion and exclusion criteria, a total of 23 studies involving 2350 patients were included in this meta-analysis. Additionally, the characteristics of these 23 included studies are summarized in Table 1. As could be seen, the sample size of these 23 studies ranged from 30 to 214, with a mean of 102.2. Meanwhile, these studies, which were published from 2014 to

Figure 3. Forest plot reflecting the association between DFS, RFS and PVT1 expression level in cancer. DFS = disease-free survival, RFS = recurrence-free survival.
2017, were from different countries, including 22 in China and 1 in Japan. Among the included studies, six focused on gastric cancer, three on non-small cell lung cancer (NSCLC), three on hepatocellular carcinoma (HCC), two on bladder cancer, two on pancreatic cancer, two on colorectal cancer (CRC), two on esophageal squamous cell carcinoma, and respectively one on small cell lung cancer, osteosarcoma, and cervical cancer. Besides, PVT1 expression was measured in cancerous specimens. All diagnoses of LNM, DM and differentiation grade were pathologically confirmed.

3.2. High PVT1 expression was correlated with shorter OS
Cumulative meta-analysis was performed to assess the function of PVT1 in the OS for cancer patients. Eighteen of the included studies covering 2108 patients had reported the relationship between OS and PVT1 expression. Typically, a significant association was observed between PVT1 expression and OS in cancer patients (pooled HR = 1.99, 95% CI: 1.73–2.28; Fig. 2). In addition, no significant heterogeneity was discovered among the eligible studies (I² = 0%, PQ = 0.608). Such results demonstrated that cancer patients with high PVT1 expression might be associated with a shorter OS. It could be discovered from the analysis results that PVT1 expression was an independent factor of OS among cancer patients.

3.3. High PVT1 expression was correlated with shorter DFS and RFS
Cumulative meta-analysis was also carried out to determine the role of PVT1 in disease-free survival (DFS) of 780 cancer patients and in recurrence-free survival (RFS) of 303 cancer patients from the eligible studies (Fig. 3). Statistical analyses revealed that PVT1 expression was associated with DFS (pooled HR = 1.76, 95% CI: 1.45–2.14), and RFS (pooled HR = 1.74, 95% CI: 1.26–2.39) of cancer patients. In addition, no significant heterogeneity was identified among the eligible studies. Therefore, our data indicated that PVT1 expression was an independent factor of DFS and RFS among cancer patients, and that high PVT1 expression was associated with shorter DFS and RFS.

3.4. High PVT1 expression was remarkably correlated with tumor size
Seventeen studies had reported the number of patients with larger tumor size based on different PVT1 expression levels. Typically, significant heterogeneity was observed among these 17 studies (I² = 0%, PQ = 0.936, Fig. 4), so the random effects model was used in the meta-analysis. The results suggested that there was a marked association between PVT1 expression level and larger tumor size (OR = 1.47, 95% CI: 1.02–2.11). Besides, difference in the tumor size between the high and low expression groups was statistically significant. Such findings revealed that cancer
patients with high PVT1 expression might be correlated with larger tumor size.

3.5. High PVT1 expression was markedly related to poor differentiation grade

A total of 1429 cancer patients from thirteen eligible studies were collected and analyzed. The fixed effects model was adopted since there was limited heterogeneity ($I^2=21.3\%$, $P_Q=0.228$). The OR, which was expressed as high PVT1 expression group versus low PVT1 expression group, was 1.79 (95% CI: 1.39–2.30, Fig. 5). Difference in the incidence of poor differentiation grade between these 2 groups was statistically significant. The results suggested that high PVT1 expression was dramatically related to the poor differentiation grade for cancer patients.

3.6. High PVT1 expression was evidently correlated with advanced tumor stage

A total of 1966 patients from twenty-one studies were included to detect the relationship between PVT1 expression level and tumor stage in this meta-analysis. As could be figured out, an evident relationship was found between high PVT1 expression and advanced tumor stage in cancer patients (pooled OR = 3.28, 95% CI: 2.46–4.38, Fig. 6) with obvious heterogeneity ($I^2=44.6\%$, $P_Q=0.010$). Subgroup analysis was conducted based on the cancer type due to the presence of heterogeneity, which revealed significant associations between PVT1 expression and advanced tumor stage in gastric cancer (GC, OR = 2.72, 95% CI: 1.57–4.70), non-small cell lung cancer (NSCLC, OR = 3.66, 95% CI: 2.03–6.62), hepatocellular carcinoma (HCC, OR = 2.33, 95% CI: 1.14–4.33) and other cancer types (OR = 4.02, 95% CI: 2.53–6.39). Taken together, the above results indicated that, the high PVT1 expression group was associated with advanced tumor stage compared with that in the low PVT1 expression group.

3.7. High PVT1 expression was notably correlated with LNM

A total of 1388 cancer patients from thirteen eligible studies were collected and analyzed. The random effects model was adopted for the significant heterogeneity ($I^2=66.5\%$, $P_Q=0.000$). The OR, which was expressed as high PVT1 expression group versus low PVT1 expression group, was 2.67 (95% CI: 1.66–4.29, Fig. 7). Subgroup analysis indicated that PVT1 expression was an independent factor for LNM in GC (OR = 2.15, 95% CI: 1.36–3.41) and NSCLC (OR = 3.12, 95% CI: 1.64–5.95) patients without heterogeneity. According to the results, difference in the LNM incidence between the 2 groups was statistically significant, and that high PVT1 expression was remarkably correlated with LNM for cancer patients.

3.8. High PVT1 expression was evidently associated with DM

The correlations between PVT1 expression and DM are presented in Figure 8. Three studies with 835 patients had declared the association between PVT1 expression and DM. The correlations between PVT1 expression and DM are presented in Figure 8. Three studies with 835 patients had declared the association between PVT1 expression and DM.
number of cancer patients with DM. Significant heterogeneity was detected among these studies, and thus the random-effects model was applied ($I^2 = 58.2\%, P_{I^2} = 0.019$). The analysis showed that a pooled OR was 4.00 (95% CI: 1.39–11.50, high versus low PVT1 expression; Fig. 8). Meanwhile, meta-regression analysis and subgroup analysis (GC or other cancer) were also performed to explore the potential sources of heterogeneity. In the subgroup analysis, significant association was found between PVT1 expression and DM in GC (OR=2.51, 95% CI: 1.13–5.56) without heterogeneity. As a result, the number of patients with DM was evidently increased in the high PVT1 expression group. These results revealed that patients with high PVT1 expression were markedly associated with DM, especially for the GC patients.

3.9. Publication bias

Subsequently, the potential publication bias was evaluated using a Begg’s funnel plot. The diagram of the Begg’s funnel plot (Fig. 9) did not reveal any evidence of obvious asymmetry for LNM. Similarly, there was no evidence for significant publication bias in terms of DM (Fig. 10).

4. Discussion

Great improvements have been made in cancer detection and treatment; however, the 5-year survival rate remains relatively low for most cancers. Typically, most cancers eventually develop metastasis, including LNM and DM, which is an important indicator of prognosis. Moreover, LNM and DM are of important significance for tumor-node-metastasis (TNM) staging, and hotspot-molecular biomarkers play critical roles in cancer prediction and treatment. However, the precise mechanism underlying metastasis remains uncertain. Therefore, it is of significant necessity to find the new molecular markers predictive of tumor metastasis. Some lncRNAs have the potential to serve as biomarkers for diagnosing and monitoring tumors due to their specific expression during tumor occurrence and development.

Previous studies show that PVT1 is a critical oncogene in a variety of human cancers, including CRC, osteosarcoma, HCC, pancreatic cancer, and GC. Recent advances have confirmed that high PVT1 expression is associated with advanced tumor stage and poor survival in GC and NSCLC. In addition, Chen et al. found that overexpression of PVT1 could promote the proliferation, cell cycle progression, and the migration of melanoma cells. Moreover, Gao et al. found that after transfected with PVT1 siRNA, the proliferation, migration, and invasion of cervical cancer cells were greatly decreased. These studies suggest that PVT1 can potentially serve as an important prognostic factor in cancer patients. In this meta-analysis, the clinicopathologic significance and prognostic value

Figure 6. Forest plot reflecting the correlation between tumor stage and PVT1 expression level in cancer. PVT1 = Plasmacytoma variant translocation 1.
Figure 7. Forest plot reflecting the correlation between LNM and PVT1 expression level in cancer. LNM = lymph node metastasis, PVT1 = Plasmacytoma variant translocation 1.

Figure 8. Forest plot reflecting the relationship between DM and PVT1 expression level in cancer. DM = distant metastasis, PVT1 = Plasmacytoma variant translocation 1.
of PVT1 in cancer patients were investigated. Detecting genes closely related to prognosis and tissue differentiation would help to better understand the mechanism of tumorigenesis. This meta-analysis would provide a foundation for research into the therapeutic value of PVT1 in cancers.

A total of 2350 cancer patients from twenty-three eligible studies were collected and analyzed in this study. The most related lncRNA studies were from China after retrieving the three global science databases. According to the inclusion and exclusion criteria, 10 tumor types in 23 eligible studies, including 22 from China and 1 from Japan, had met the criteria. Consequently, the results might be only suitable for the Han population or Asian population. Thus, studies from other ethnicities or countries are needed to determine whether the results are applicable to all populations. A random effects model or fixed effects model was used in this meta-analysis depending on the results of heterogeneity analysis. It was found that high PVT1 expression might indicate poorer prognosis for cancer patients. HRs from Cox multivariate analyses were combined, and a significant difference was found in OS between high and low PVT1 expression groups. It was found that high PVT1 expression was remarkably associated with DFS and RFS in different types of cancer. Furthermore, it was revealed in this meta-analysis that high PVT1 expression was evidently correlated with larger tumor size, poor differentiation grade, advanced tumor stage, LNM, and DM. The heterogeneity discovered in this

![Figure 9. Begg's funnel plot showing the publication bias for PVT1 expression and lymph node metastasis. PVT1 = Plasmacytoma variant translocation 1.](image)

![Figure 10. Begg's funnel plot showing the publication bias for PVT1 expression and distant metastasis. PVT1 = Plasmacytoma variant translocation 1.](image)
study could mainly be attributed to the various types of cancers in this meta-analysis. Taken together, our meta-analysis suggested that PVT1 might be used as an unfavorable prognostic biomarker for most cancers.

5. Limitations
Several limitations must be taken into account while interpreting the conclusions of this meta-analysis. Firstly, most included studies were from China, and only one was from Japan; therefore, our data might not be globally applicable. Secondly, only small sample size of cancer type and number was included in this meta-analysis, so larger-scale studies would be necessary to verify the obtained results. Thirdly, the criteria for high expression differed among these studies, and it was difficult to obtain the same value. Consequently, further study will be needed to confirm the function of PVT1 in various cancers.

6. Conclusions
Taken together, our findings indicate that a high PVT1 expression level is correlated with poor OS, DFS, RFS, LNM, DM, differentiation grade, larger tumor size, and tumor stage in multiple cancers. Therefore, PVT1 expression is a potentially useful biomarker to predict the prognosis and metastasis for cancer patients.

Author contributions
CM and XGN search the electronic databases of Pubmed, OVID and Web of Science. CM and YLW evaluated all of the included studies and extracted the data independently. CM and DPW extracted and examined the data from the original articles independently. QDL resolved the disagreements in the literature assessment and CM was a major contributor in writing the manuscript. All authors read and approved the final manuscript.

Data curation: Chao Ma, Xing-Guo Nie, and Yan-Li Wang.
Funding acquisition: Qiu-dong Liang.
Investigation: Chao Ma, Xing-Guo Nie, Yan-Li Wang, Da-Peng Wu, and Qiu-dong Liang.
Methodology: Chao Ma, Xing-Guo Nie, Yan-Li Wang, Da-Peng Wu, and Qiu-dong Liang.
Project administration: Chao Ma.
Software: Chao Ma, Xing-Guo Nie, and Qiu-dong Liang.
Supervision: Qiu-dong Liang.
Writing – original draft: Chao Ma.
Writing – review & editing: Qiu-dong Liang.

References
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7–30.
[2] Johnson P, Lipovich L, Grander D, et al. Evolutionary conservation of long non-coding RNAs: sequence, structure, function. Biochim Biophys Acta 2014;1840:1063–71.
[3] Fan YH, Fang H, Ji CX, et al. Long noncoding RNA CCAT2 can predict metastasis and poor prognosis: a meta-analysis. Clin Chem Acta 2014;466:120–6.
[4] Li T, Chen Y, Zhang J, et al. LncRNA TUG1 promotes cells proliferation and inhibits cells apoptosis through regulating AURKA in epithelial ovarian cancer cells. Medicine (Baltimore) 2018;97:e12131.
[5] Zhou Y, Wang DL, Pang Q. Long noncoding RNA SPRY4-IT1 is a prognostic factor for poor overall survival and has an oncogenic role in glioma. Eur Rev Med Pharmacol Sci 2016;20:3035–9.
[6] Zheng Y, Gao Y, Li X, et al. Long non-coding RNA NAP1L6 promotes tumor progression and predicts poor prognosis in prostate cancer by targeting Inhibin-beta A. Onco Targets Ther 2018;11:4963–77.
[7] Yao X, Yan C, Zhang L, et al. LncRNA ENST00003 promotes proliferation, survival, and migration by activating PI3K/Akt/mTOR signaling pathway in atherosclerosis. Medicine (Baltimore) 2018;97:e0473.
[8] Ma Z, Huang H, Xu Y, et al. Current advances of long non-coding RNA highly upregulated in liver cancer in human tumors. Onco Targets Ther 2017;10:4711–7.
[9] Fan Y, Yan T, Chai Y, et al. Long noncoding RNA HOTTIP as an independent prognostic marker in cancer. Clin Chim Acta 2018;482:224–30.
[10] Du Z, Fei T, Verhaak RG, et al. Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer. Nat Struct Mol Biol 2013;20:908–13.
[11] Takahashi Y, Sawada G, Kurashige J, et al. Amplification of PVT1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers. Br J Cancer 2014;110:164–71.
[12] Carramusa L, Contino F, Ferro A, et al. The PVT-1 oncogene is a Myc protein target that is overexpressed in transformed cells. J Cell Physiol 2007;213:511–8.
[13] Liu E, Liu Z, Zhou Y, et al. Overexpression of long non-coding RNA PVT1 in ovarian cancer cells promotes cisplatin resistance by regulating apoptotic pathways. Int J Clin Exp Med 2015;8:20565–72.
[14] Zhang XW, Bu F, Liu L, et al. Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Biochem Biophys Res Commun 2015;462:227–32.
[15] Fan YH, Ji CX, Xu B, et al. Long noncoding RNA activated by TGF-beta in human cancers: a meta-analysis. Clin Chim Acta 2017;468:30–16.
[16] Altman DG, McShane LM, Sauerbrei W, et al. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 2012;9:e1001216.
[17] Zhang L, Li X, Yan H, et al. Salivary matrix metalloproteinase (MMP)-8 as a biomarker for periodontitis: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e9642.
[18] Zhong Y, Chen Z, Guo S, et al. TUG1, SPRY4-IT1, and HULC as valuable prognostic biomarkers of survival in cancer: a PRISMA-compliant meta-analysis. Medicine (Baltimore) 2017;96:e5838.
[19] Chen J, Li Y, Zheng Q, et al. Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer. Cancer Lett 2017;388:208–19.
[20] Cui D, Yu CH, Liu M, et al. Long non-coding RNA PVT1 as a novel biomarker for diagnosis and prognosis of non-small cell lung cancer. Tumour Biol 2016;37:4127–34.
[21] Cui Y, Liu L, Chen J, et al. Increased expression of long non-coding RNA PVT1 correlates with clinical progression and poor prognosis in bladder cancer. Int J Clin Exp Pathol 2017;10:3265–71.
[22] Ding J, Li D, Gong M, et al. Expression and clinical significance of the long non-coding RNA PVT1 in human gastric cancer. Onco Targets Ther 2014;7:1625–30.
[23] Ding C, Yang Z, Lv Z, et al. Long non-coding RNA PVT1 is associated with tumor progression and predicts recurrence in hepatocellular carcinoma patients. Onco Lett 2015:9:953–63.
[24] Huang C, Yu W, Wang Q, et al. Increased expression of the lncRNA PVT1 is associated with poor prognosis in pancreatic cancer patients. Minerva Med 2015;106:143–9.
[25] Huang C, Liu S, Wang H, et al. LncRNA PVT1 overexpression is a poor prognostic biomarker and regulates migration and invasion in small cell lung cancer. Am J Transl Res 2016;8:3025–34.
[26] Huang T, Liu HW, Chen JQ, et al. The long noncoding RNA PVT1 functions as a competing endogenous RNA by sponging miR-186 in gastric cancer. Biomed Pharmacother 2017;88:302–8.
[27] Kong R, Zhang EB, Yin DD, et al. Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16. Mol Cancer 2015;14:82.
[28] Lan T, Yan X, Li Z, et al. Long non-coding RNA PVT1 serves as a competing endogenous RNA for miR-186-5p to promote the tumorigenesis and metastasis of hepatocellular carcinoma. Tumour Biol 2017;39:1010428317705338.
[29] Li Q, Dai Y, Wang F, et al. Differentially expressed long non-coding RNAs and the prognostic potential in colorectal cancer. Neoplasma 2016;63:977–83.
[30] Li PD, Hu JL, Ma C, et al. Upregulation of the long non-coding RNA PVT1 promotes esophageal squamous cell carcinoma progression by acting as a molecular sponge of miR-203 and LASP1. Oncotarget 2017;8:34164–76.
[31] Song J, Wu X, Liu F, et al. Long non-coding RNA PVT1 promotes glycolysis and tumor progression by regulating miR-497/M2 axis in osteosarcoma. Biochem Biophys Res Commun 2017;490:217–24.
[32] Wan L, Sun M, Liu GJ, et al. Long noncoding RNA PVT1 promotes non-small cell lung cancer cell proliferation through epigenetically regulating LATS2 Expression. Mol Cancer Ther 2016;15:1082–94.

[33] Wang F, Yuan JH, Wang SB, et al. Oncofetal long noncoding RNA PVT1 promotes proliferation and stem cell-like property of hepatocellular carcinoma cells by stabilizing NOP2. Hepatology 2014;60:1278–90.

[34] Xu MD, Wang Y, Weng W, et al. A positive feedback loop of IncRNA-PVT1 and FOXM1 facilitates gastric cancer growth and invasion. Clin Cancer Res 2017;23:2071–80.

[35] Yang YR, Zang SZ, Zhong CL, et al. Increased expression of the IncRNA PVT1 promotes tumorigenesis in non-small cell lung cancer. Int J Clin Exp Pathol 2014;7:6929–35.

[36] Yuan CL, Li H, Zhu L, et al. Aberrant expression of long noncoding RNA PVT1 and its diagnostic and prognostic significance in patients with gastric cancer. Neoplasma 2016;63:442–9.

[37] Zhang D, Sun G, Zhang H, et al. Long non-coding RNA PVT1 facilitates cervical cancer progression through negative modulation of miR-128-3p. Int J Clin Exp Pathol 2017;10:4522–9.

[38] Zhao L, Kong H, Sun H, et al. IncRNA-PVT1 promotes pancreatic cancer cells proliferation and migration through acting as a molecular sponge to regulate miR-448. J Cell Physiol 2018;233:4044–55.

[39] Zheng X, Hu H, Li S. High expression of IncRNA PVT1 promotes invasion by inducing epithelial-to-mesenchymal transition in esophageal cancer. Oncol Lett 2016;12:2357–62.

[40] Zhuang C, Li J, Liu Y, et al. Tetracycline-inducible shRNA targeting long non-coding RNA PVT1 inhibits cell growth and induces apoptosis in bladder cancer cells. Oncotarget 2015;6:41194–203.

[41] Lin Z, Chen W, Chen Y, et al. A new classification of lymph node metastases according to the lymph node stations for predicting prognosis in surgical patients with esophageal squamous cell carcinoma. Oncotarget 2016;7:76261–73.

[42] Guan H, Mei Y, Mi Y, et al. Downregulation of IncRNA ANRIL suppresses growth and metastasis in human osteosarcoma cells. Oncotarget 2018;11:4893–9.

[43] Mirzaei H, Gholamin S, Shahidsales S, et al. MicroRNAs as potential diagnostic and prognostic biomarkers in melanoma. Eur J Cancer 2016;53:25–32.

[44] Fan YH, Ye MH, Wu L, et al. Overexpression of miR-98 inhibits cell invasion in glioma cell lines via downregulation of IKKepsilon. Eur Rev Med Pharmacol Sci 2015;19:3593–604.

[45] Qi P, Du X. The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol 2013;26:155–65.

[46] Chen X, Gao G, Liu S, et al. Long noncoding RNA PVT1 as a novel diagnostic biomarker and therapeutic target for melanoma. Biomed Res Int 2017;2017:7038579.

[47] Gao YL, Zhao ZS, Zhang MY, et al. Long noncoding RNA PVT1 facilitates cervical cancer progression via negative regulating of miR-424. Oncol Lett 2017;25:1391–8.